Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Molecular Medicine

Volume 10 Issue 4
ISSN: 1566-5240
eISSN: 1875-5666


   All Titles

  Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
  pp.430-439 (10) Authors: H. Matthes, W.E. Friedel, P.R. Bock, K.S. Zanker

Mistletoe is often used as complementary therapy in oncology. The anti-tumor effects of mistletoe (Iscador®) are well documented in-vitro in respect to inhibition of cell proliferation, induction of apoptosis, segmental activation of immune competent cells and trapping of chemotherapeutic drugs within cancer cells by modulating the inhibitory potential of P-glycoprotein (P-gp)-mediated transport of cell toxifying substances (cytotoxic drugs). However, the clinical activity of mistletoe treatment remains still controversial. Implementation of mistletoe therapy as supportive care into anti-cancer programs should be based on the best evidence and must continually be evaluated to ensure safety, efficacy, collection of new data, and cost-effectiveness. Useful domains that can be evaluated include symptom control, adherence to conventional treatment protocols, quality of life, individual outcome and potential advantages of a whole-system health approach. Here we report the results of a multicenter, controlled, retrospective and observational pharmacoepidemiological study in patients suffering from a pancreatic carcinoma. After surgery the patients were treated by adjuvant chemotherapy with gemcitabine supported by Iscador®, or with gemcitabine alone, or any other best of care, but not including Iscador®. Using a novel methodological pharmaco-epidemiological design and statistical approach it could be shown that Iscador® offers benefits - symptom control, overall survival - as supportive care within gemcitabine protocols of patients with surgically resected pancreatic carcinoma.

  Keywords: Pancreatic carcinoma, pharmaco-epidemiological study, gemcitabine, Iscador®, supportive care, integrative oncology, symptom control, overall survival, mistletoe
  Affiliation: Institute of Immunology&Experimental Oncology, 10, Stockumerstrabe, 58448 WITTEN/Germany.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers